Document:

Exhibit 10.2

 

First Amendment
to Consulting Agreement

 

This First Amendment (“Amendment”)
to the consulting Agreements signed on June 18, 2013, and is effective as of March 30, 2014 (the “Amendment Date”),
and is entered into by and among:

 

		(i)	Dalian Wanchun Pharmaceutical Co., Ltd., a China corporation, having a principal place
of business at No. 9 Liaohe East Road, Dalian Economic Development Zone, Dalian, China 116025 (“Dalian”);

 

		(ii)	GKOL, Inc., a California corporation, with an office at 13932 Dodder
Court, Poway, CA 92064 (“GKOL”); and

 

		(iii)	BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with
an office at 48 Wall Street, 11th Floor, New York, New York 10005 USA (“BeyondSpring”).

 

WITNESSETH:

 

WHEREAS,
GKOL and Dalian are parties to the Consulting Agreement, with an effective date of June 18, 2013 (the “Agreement”);

 

WHEREAS,
the Agreement sets forth certain rights and obligations of the parties relating to the provision of certain Services (as defined
in the Agreement) by GKOL to Dalian; and

 

WHEREAS,
BeyondSpring, a US corporate affiliate of Dalian, took over the rights and responsibility of Dalian on Plinabulin (NPI-2358) and
the Agreement. BeyondSpring wishes to engage GKOL to perform certain Services under the Agreement for BeyondSpring. Dalian signed
the Agreement and made payments on behalf of BeyondSpring;

 

WHEREAS,
the parties hereto desire to amend the Agreement to add BeyondSpring as the client, and remove Dalian as the client, as more fully
described below;

 

NOW
THEREFORE, in consideration of the covenants contained herein the parties hereto, intending to be legally bound hereby, agree as
follows:

 

		1.	BeyondSpring Pharmaceuticals, Inc. is hereby added as the sole client party
to the Consulting Agreement.

 

		2.	All instances of the words “Dalian Wanchun Pharmaceutical Co. Ltd”
in the Agreement are hereby deleted and replaced with the word “BeyondSpring Pharmaceuticals, Inc.”.

 

		3.	Except to the extent expressly amended hereby, all other terms and conditions
of the Agreement are hereby ratified and the parties agree and acknowledge that they are subject to the Agreement and the same
is in full force and effect.

 

		4.	This Amendment and the Agreement, constitute
the entire agreement between the parties with respect to the subject matter contained therein, and together, supersede and replace
any and all prior and contemporaneous understandings, arrangements and agreements, whether oral or written, with respect
to the subject matter.

 

		5.	This Amendment shall be construed and interpreted in accordance with the laws of the State of
Maryland without giving effect to its principles of conflicts of laws.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties
have caused this Amendment to be executed by their duly authorized representatives, to be effective as of the Amendment Date regardless
of the date actually signed.

 

	GKOL, Inc.,	 	Dalian Wanchun Pharmaceutical Co., Ltd.
	 	 	 
	 	 	 	 	 
	By: 	/s/ G. Kenneth Lloyd	 	By:	/s/ Lan Huang
	Name: Ken Lloyd, Ph.D.	 	Name: Lan Huang, Ph.D.
	Title: Vice President 	 	Title: CEO
	Date: March 30, 2014	 	Date: March 30, 2014
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	BeyondSpring Pharmaceuticals, Inc.
	 	 	 	 
	 	 	 	 
	 	 	 	By:	/s/ Lan Huang
	 	 	 	Name: Lan Huang, Ph.D.
	 	 	 	Title: CEO
	 	 	 	Date: March 30, 2014Exhibit 10.3

 

Second Amendment to

Consulting Agreement

 

This Second Amendment (“Amendment”)to
the consulting Agreements signed on June 18, 2013, and is effective as of June 1, 2015 (the “Amendment Date’). Because
three way agreement was signed on March 30, 2014 and stated that BeyondSpring Pharmaceuticals, Inc. is taking over full responsibility
and rights, so this agreement is only entered into by and among:

 

	(i)    	GKOL, Inc., a California corporation, with an office at 13932 Dodder Court, Poway, CA 92064 (“GKOL”); and

 

	(ii)  	BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an office at 28 Liberty Street, 39th Floor, New York,
New York 10005 USA (‘BeyondSpring”).

 

WITNESSETH:

 

WHEREAS, the parties hereto desire to amend
the Agreement Exhibit B as follows;

 

NOW THEREFORE, inconsideration of
the covenants contained herein the parties hereto, intending to be legally bound hereby, agree as follows:

 

EXHIBIT B 

Compensation

 

As compensation for services rendered
pursuant to the terms of this Agreement, the Company shall pay the Consultant the sum of three hundred thousand USD per
annum, paid on a monthly basis.

 

In return for this compensation, the
consultant shall work no less than 160 hours per month on behalf of Company.

 

Vacation time includes 4 weeks annual vacation
plus 10 statutory holidays.

 

Company will pay for the medical insurance
for G. Kenneth Lloyd and Kathleen O’Laughlin Lloyd, upon receipt of invoices.

 

Upon presentation of receipts, Company shall
reimburse Consultant for:

 

	     ·        	All payments made to third parties on behalf of Company

 

	     ·        	All pre-authorized travel expenses at the following rate:

 

	     ·        	Full reimbursement for airfare (economy for trips of less than 5 hours duration; business class or higher for all trips of 5 hours
or longer duration) and other travel (including but not limited to taxis and trains)

 

	     ·        	Full reimbursement for hotels, meals and generally acceptable other travel expenses

 

    	 

    	 

    

 

 

This Amendment shall be construed
and interpreted in accordance with the laws of the State of Delaware without giving effect to its principles of conflicts of laws.

 

IN WITNESS WHEREOF, the parties
have caused this Amendment to be executed by their duly authorized representatives, to be effective as of the Amendment Date.

 

	GKOL, Inc.,	 	BeyondSpring Pharmaceuticals, Inc.
	 	 	 
	/s/ G. Kenneth Lloyd	 	/s/ Lan Huang
	 	 	 
	 	 	 
	Name: G. Kenneth Lloyd, Ph.D.	 	Name: Lan Huang, Ph.D.
	 	 	 
	Title: Vice President	 	Title: CEO
	 	 	 
	Date: May 2, 2015	 	Date: May 2, 2015Exhibit 10.4

 

 

EXECUTION COPY

 

TERMINATION AGREEMENT

To

 ASSET PURCHASE AGREEMENT

 

This Termination Agreement to Asset Purchase
Agreement (this "Agreement") is made and entered into as of February 2, 2015 (the "Effective Date") by and
among BeyondSpring Inc., a Cayman Islands exempted company (the "Company"), Dalian Wanchun Biotechnology Co., Ltd. (hereinafter
called "Wanchun") and Nereus Pharmaceuticals, Inc. (hereinafter called "Nereus"). In the event that the Company's
IPO (as defined below) is not consummated within three (3) years following the Effective Date, the provisions of this Agreement
shall not take effect. Each of the Company, Wanchun and Nereus is referred to herein individually as a "party" and collectively
as the "parties".

 

WHEREAS, Wanchun and Nereus entered into
an Asset Purchase Agreement on January 30, 2013 in respect of the purchase of certain assets by Wanchun from Nereus (the "Purchase
Agreement"). Any capitalized terms used but not defined herein shall have the meanings set forth in the Purchase Agreement.

 

WHEREAS, the parties wish to terminate
the Purchase Agreement and enter into this Agreement, as set forth herein.

 

NOW THEREFORE, in consideration of the
premises and mutual covenants contained herein, and other good and valuable consideration, the sufficiency and receipt of which
is hereby acknowledged, Wanchun and Nereus agree that the Purchase Agreement is hereby amended as follows:

 

		1.	Effective as of immediately prior to the consummation of the Company's first underwritten public
offering of its equity securities pursuant to the United States Securities Act of 1933, as amended (the "Effective Time",
and such public offering, the "IPO"), the Purchase Agreement shall terminate and be of no further force and effect, and
thereafter none of the Company, Wanchun or any of their affiliates shall have any obligations thereunder except as set forth herein
(except that, for clarity, the sale, transfer, conveyance, assignment and delivery of all Transferred Assets under the Purchase
Agreement and Ancillary Agreements shall survive and remain in full force and effect).

 

		2(a).	At the Effective Time, the Company shall issue and allot such number of ordinary shares representing
10% of the Company's fully-diluted equity capitalization immediately prior to the IPO (the "Nereus Shares") to a single
corporate entity designated by Nereus (the "Nereus Designee"). Nereus shall promptly furnish to the Company such information
regarding the Nereus Designee as the Company may reasonably request in connection with the IPO.

 

 

Page 1 of 5

 

    	 

    	 

    

 

EXECUTION COPY

 

		2(b).	The Nereus Designee shall not, and Nereus shall cause the Nereus Designee not to, Transfer (as
defined below) the Nereus Shares to any other Person prior to the IPO.

 

		3(a).	Without limiting Section 2(b) above, Nereus acknowledges and agrees, on behalf of itself and the
Nereus Designee, and shall ensure, that the Nereus Designee shall not, and shall cause any subsequent direct or indirect transferee
of the Nereus Shares (by any form of Transfer) to agree (each a "Transferee"), as a condition to any Transfer of the
Nereus Shares, not to, until the date that is 180 days after the date of the final prospectus relating to the registration by the
Company for its own behalf of any equity securities under the Securities Act of 1933, as amended (the "Securities Act"),
on a registration statement on Form S-1 or Form F-1, or such other period as may be requested by the Company or an Underwriter
(as defined below), including to accommodate regulatory restrictions on (1) the publication or other distribution of research reports,
and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4)
or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto (such period, the "Specified Time Period"),
without the prior written consent of the managing underwriter in such registered offering:

 

(i)         
lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to
sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any of the
Nereus Shares or any other of the Company's equity securities or any securities convertible into or exercisable or exchangeable
(directly or indirectly) for any of the Nereus Shares or the Company's other equity securities (whether such shares or any such
securities are then owned by the Nereus Designee or any of its Transferees or are thereafter acquired), or

 

(ii)
        enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of the Nereus Shares or any other of the Company's equity securities;

 

in each case, whether any such
transaction described in clause (i) or (ii) above is to be settled by delivery of equity securities other securities, in cash,
or otherwise (each, a "Transfer"). The underwriters in connection any registration described in this Section 3(a) (each,
an "Underwriter") are intended third party beneficiaries of this Section 3(a) and shall have the right, power and authority
to enforce the provisions hereof as though they were a party hereto. The Nereus Designee or any of its Transferees further agrees
to execute such agreements as may be reasonably requested by the Underwriters in connection with any registration described in
this Section 3(a) or that are necessary to give further effect thereto. For clarity, the foregoing shall not restrict Transfer
of the Nereus Shares by the Nereus Designee following the end of the Specified Time Period, to the extent permitted by applicable
law. Following the end of the Specified Time Period through the one-year anniversary of the Effective Time, the Company agrees
to

 

 

Page 2 of 5

 

    	 

    	 

    

 

EXECUTION COPY

 

continue to be subject to the reporting
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to file
on a timely basis all reports and other documents requested to be filed by it under Section 13 or 15(d) of the Exchange Act (and
to satisfy any future criteria under Rule 144(c)(1) of the Securities Act or its successor provisions) and, if requested by the
Nereus Designee, the Company agrees to use its commercially reasonable efforts to cooperate with the Nereus Designee to effect
the Transfer of the Nereus Shares in compliance with applicable law in a manner exempt from registration under the Securities Act;
provided that the Nereus Designee shall first deliver such documentation to the Company as it may reasonably request in connection
with such Transfer.

 

		3(b).	If at any time following the one-year anniversary of the Effective Time, the Nereus Designee requests
that the Company file a registration statement for a public offering of the Registrable Common Stock (as defined herein), then,
at the Company's expense, the Company shall use its commercially reasonable efforts to register under the Securities Act on a registration
statement (a "Registration"), for a public sale in accordance with the method of disposition specified in such notice,
the number of shares of Registrable Common Stock specified in such notice; provided, however, that the Company shall only be obligated
to use its commercially reasonable efforts to effect one such Registration under the terms of this Agreement. For purposes of this
Paragraph 3(b), "Registrable Common Stock" means the Nereus Shares; provided, however, that any such Nereus Shares shall
cease to be Registrable Securities (i) upon any sale of Nereus Shares pursuant to a registration statement or Rule 144 under the
Securities Act or (ii) if such securities may be sold without restriction pursuant to Rule 144.

 

		4.	Nereus acknowledges that to its knowledge it sold, transferred, conveyed, assigned and delivered
to Wanchun all Intellectual Property of Nereus related to the Program at the time of the Closing. At the Company's expense, Nereus
(or its successor or assign), will use its reasonable efforts to take, or cause to be taken, all actions and to do, or cause to
be done, all things necessary or desirable under applicable law to consummate the transactions contemplated by the Purchase Agreement,
including (a) preparing and filing as promptly as practicable with any Governmental Body or other Third Party all documentation
to effect all necessary filings, notices, petitions, statements, registrations, submissions of information, applications and other
documents, (b) obtaining and maintaining all approvals, consents, registrations, permits, authorizations and other confirmations
required to be obtained from any Governmental Body or other Third Party that are necessary, proper or advisable to consummate the
transactions contemplated by the Purchase Agreement, and (c) facilitating the orderly transfer of the Transferred Assets to Wanchun
including the development, manufacturing (including reports, processes and materials) and storage activities related to the Company
Compound and Products. In addition, all costs and expenses incurred by Nereus or its Representatives in connection with fulfilling
any of the Company's requests under this Section 4, including attorneys' fees, shall be borne

 

 

Page 3 of 5

 

    	 

    	 

    

 

EXECUTION COPY

 

by the Company and shall be reimbursed
by the Company promptly (but in any event no more than thirty (30) days) following receipt of an invoice from Nereus or its Representatives
of such costs and expenses.

 

		5.	Each party represents and warrants to the other party, as of the Effective Time, that: (i) it has
the absolute and unrestricted right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder,
and (ii) this Agreement constitutes the legal, valid and binding obligation of such party, enforceable against such party in accordance
with its terms, subject to (a) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (b)
rules of law governing specific performance, injunctive relief and other equitable remedies.

 

		6.	This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings,
both written and oral, among or between any of the parties with respect to the subject matter hereof (other than, for clarity,
the Purchase Agreement as expressly terminated hereby). This Agreement may be executed in counterparts, each of which so executed
shall be considered an original. Once signed, any reproduction of this Agreement made by reliable means (for example, electronic
image, photocopy, or facsimile) is considered an original.

 

		7.	Governing Law. This Agreement shall be governed by, and construed in accordance with, the
laws of the State of California, regardless of the laws that might otherwise govern under applicable principles of conflicts of
laws thereof.

 

		8.	Specific Performance. Each of the parties hereto agrees that this Agreement is intended
to be legally binding and specifically enforceable pursuant to its terms and that Nereus, Wanchun and the Company would be irreparably
harmed if any of the provisions of this Agreement are not performed in accordance with their specific terms and that monetary damages
would not provide adequate remedy in such event. Accordingly, in addition to any other remedy to which a non-breaching party may
be entitled at law, a non-breaching party shall be entitled to injunctive relief to prevent breaches of this Agreement and to specifically
enforce the terms and provisions hereof without the necessity of demonstrating the inadequacy of monetary damages.

 

		9.	Fortis Exculpation. The Company and Wanchun acknowledge that Fortis Advisors LLC ("Fortis")
is solely acting in an administrative capacity as the agent and attorney-in-fact for and on behalf of Nereus and its former stockholders.
As such, the Company and Wanchun acknowledge and agree that Fortis shall not be required to expend or risk its own funds or otherwise
incur any financial liability or any other form of liability in the exercise or performance of any of its powers, rights, duties,
or privileges or administration of its duties set forth hereunder.

 

[Signature Page Follows]

 

Page 4 of 5

 

    	 

    	 

    

 

EXECUTION COPY

 

ACKNOWLEDGED AND AGREED:

 

	Dalian Wanchun Biotechnology Co., Ltd.	Nereus Pharmaceuticals, Inc.
	 	 	Executed by FORTIS ADVISORS LLC, in its capacity as agent of the former stockholders of Nereus Pharmaceuticals, Inc.
	 	 	 	 	 	 
	By	 /s/ Lan Huang	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Name	Lan Huang, Ph.D	 	Name 	/s/ Authorized Signatory 	 
	(Type or Print)	 	(Type or Print)	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Title	 CEO	 	Title 	Managing Director	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Date	2/2/2015	 	Date 	2/2/2015	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	BeyondSpring Inc.	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	By 	/s/ Lan Huang	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Name 	Lan Huang, Ph.D	 	 	 	 
	(Type or Print)	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Title	 CEO	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Date	2/2/2015	 	 	 	 

 

 

 

 

Page 5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]